Watchdog Asks HHS to Probe FDA Peptide Panel Conflicts

A consumer watchdog organization has formally requested that the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) initiate an investigation into potential conflicts of interest among members of a Food and Drug Administration (FDA) advisory committee. This committee, known as the Drug Abuse Advisory Committee (DAAC), recently made a recommendation to add six specific peptides to the FDA's list of controlled substances. The watchdog group, Public Citizen, expressed concerns that some panelists may have had financial ties to companies that stand to benefit from the regulation or prohibition of these substances, which could compromise the integrity of the committee's advice.

Public Citizen's petition, submitted on May 23, 2024, specifically targets the DAAC's recommendation concerning six peptides: tert-butyl 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-carboxylate (also known as TBHP), tert-butyl (2S)-2-amino-3-methylbutanoate, tert-butyl (2S)-2-amino-3,3-dimethylbutanoate, tert-butyl (2S)-2-amino-4-(methylthio)butanoate, tert-butyl (2R)-2-amino-3-methylbutanoate, and tert-butyl (2R)-2-amino-3,3-dimethylbutanoate. The organization argues that the FDA's process for selecting panelists for advisory committees should include more robust screening for financial and other potential conflicts of interest. The peptides in question are often used in research and development, and their classification as controlled substances could significantly impact their availability and the cost of research, potentially creating a market advantage for certain entities.

The petition highlights that the DAAC's recommendation to add these peptides to the controlled substances list was based on their potential for abuse and diversion, similar to other substances already under regulatory scrutiny. However, Public Citizen contends that the advisory process itself may have been tainted if panelists with vested interests in the outcome were allowed to vote. The group is urging the HHS OIG to review the FDA's conflict-of-interest policies and procedures for advisory committee appointments and to examine the specific disclosures and voting records of the panelists involved in the peptide recommendation. The outcome of this investigation could lead to revised protocols for FDA advisory committees, ensuring greater transparency and impartiality in future recommendations that affect public health and scientific research.

This call for investigation underscores a broader concern within public health and regulatory bodies regarding the influence of industry on scientific advisory panels. The FDA relies on these committees for expert advice on a wide range of complex issues, from drug approvals to substance scheduling. Ensuring that this advice is unbiased and based solely on scientific evidence, free from undue financial influence, is critical for maintaining public trust and safeguarding the integrity of regulatory decisions. Public Citizen's action aims to reinforce these principles and promote accountability within the federal regulatory framework governing pharmaceuticals and related substances.